The ADRC is currently recruiting participants for:

    Noble Study

    Description: This is a clinical study to evaluate an investigational drug in mild to moderate Alzheimer's disease. The investigational drug may work by protecting brain cells which could result in improved memory. adcs.org

    Study Length: 14 months

    Study Requirements
    • 55-85 years of age
    • Diagnosis of Alzheimer's disease (Mild-Moderate)
    • A study partner who will accompany the participant to all clinic visits
    • Weight of no more than 220lbs
    • Taking certain memory medication(s) for 6 months
    Contact:
    Thomas Baumgartner at 412-692-2716 or baumgartnertc@upmc.edu or
    MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu
    A4 Study

    Description: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease Trial, or A4 Study, is among a new generation of clinical trials being developed to test therapies that might prevent, or at least delay the onset of, Alzheimer's disease in cognitively normal people who may be at risk as evidenced by a PET scan. a4study.org

    Study Length: 3 years

    Study Requirements
    • 65 to 85 years of age
    • Normal thinking and memory abilities
    • Have a study partner with whom you have contact at least once a week who can answer questions about you once a year (contact may be in person or by phone)
    • Willing and able to receive IV infusions of the investigational drug (solanezumab) or a placebo every 4 weeks for 3 years
    Contact:
    MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu or
    Katy Zorich at 412-692-2730 or orchowskik3@upmc.edu
    STARBEAM Study (Lundbeck)

    Description: The primary objective of this study is to establish the efficacy of an investigational medication (Lu AE58054) as adjunctive therapy to Donepezil for symptomatic treatment of patients with mild-moderate Alzheimer's disease.

    Study Length: 7 months

    Study Requirements
    • Individuals age 50 or older with mild-moderate Alzheimer's disease
    • Not currently taking memantine
    • Stable treatment with donepezil
    • A study partner who will accompany the participant to all clinic visits
    Contact:
    MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu
    AMBAR Study

    Description: The purpose of this study is to determine whether short-term followed by long-term, low-volume plasma exchange (a process of blood filtering) is able to modify Alzheimer Disease patient's cognitive, functional, and behavioral symptoms.

    Study Length: 14 months (Six weekly plasmapheresis sessions followed by 12 monthly plasmapheresis sessions)

    Study Requirements
    • 55-85 years of age
    • Individuals with a diagnosis of mild to moderate Alzheimer's disease
    • A study partner who will accompany the participant to all clinic visits
    Contact:
    Donna Simpson, 412-692-2717 or simpsondm@upmc.edu or
    MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu


The University of Pittsburgh Alzheimer Disease Research Center (ADRC) is one of the nation's leading research centers specializing in the diagnosis of Alzheimer's disease and related disorders. Through outpatient evaluations, participants and their families receive state-of-the-art diagnostic assessments and contribute to the scientific study of Alzheimer's disease

Learn More »

Our memory evaluation is an extensive diagnostic evaluation of individuals with suspected Alzheimer's disease and other types of memory loss and/or cognitive impairment. The professionals at the ADRC understand that this is a stressful process for all and assure that individuals will be treated with sensitivity and respect.

Learn More »

Top